α-Glucosyl FP20 A86782 (Previously 860782) 6-O-α-D-Glucopyranosyl-1β,2N,3-tridodecanoyl-D-glucosamine-4-phosphate, sodium salt
Introducing α‑Glucosyl FP-20 from Avanti Research™ - an advanced, glycan‑modified FP‑20 sodium salt analog vaccine adjuvant compound.
α‑Glucosyl FP-20 refines immunotherapeutic agents' potency and selectivity of human Toll‑like receptor 4 (hTLR4), activating MyD88- and TRIF-mediated signals, inducing cytokine (e.g., IL‑6, TNF‑α) and type I interferon secretion, and promoting effective, balanced immune activation.
This compound functionalizes the C6 position of FP-20 sodium salt's glucosamine core with a glucose moiety while preserving a vastly scalable, reproducible, and streamlined synthetic composition.
In HEK‑Blue cell assays and macrophage polarization models, glycosylated FP‑20 derivatives’ potency demonstrably outperforms the parent FP‑20 in hTLR4 activation, thanks to their improved MD‑2 binding affinity and molecular recognition.
Recent studies show glyco‑FP‑20 derivatives triggering two crucial immune activation pathways: M1 macrophage polarization (via NF‑κB) and potent inflammasome-associated pyroptosis (RSC Publishing).
